Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Summary

This phase II trial is studying imatinib mesylate to see how well it works in treating patients with chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth

Timeline

Start

2002-09

Primary completion

2007-10

Completion

—

Publications

• Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62. doi: 10.1002/pbc.23031. Epub 2011 Apr 4.

Drugs

Indications